DNA - Dr. Emiel Rutgers, NL
- Sequencing [5. Molecular biology (pre-clinical)] - Dr. Peter Campbell, UK
- CGH Array [1. Detection and diagnosis] - Dr. Fabrice André, FR
RNA - Dr. Giuseppe Curigliano, IT
- Expression profiles for disease management: How can we find them? How can we apply them? - [7. Miscellaneous] - Dr. Christine Desmedt, BE
- Expression profiles for disease management: How can we find them? How can we apply them? - Dr. Laura van't Veer, NL
Emerging Technologies - Dr. Fabrice André, FR
- Integrated analysis of mRNA and miRNA profiles reveals potential new regulatory targets in breast cancer cell lines [5. Molecular biology (pre-clinical)] - Dr. Libero Santarpia, IT
- Metabolomics [7. Miscellaneous] - Dr. Catherine Oakman, IT
Circulation Markers - Dr. Philippe Bedard, CA
- Circulating nucleic acids - Dr Ludovic Lacroix, FR
- Circulating and disseminated tumour cells [7. Miscellaneous] - Dr. Michail Ignatiadis, BE
Pathology - Professor Michael Gnant, AT
- Standard bio-markers [3. Adjuvant medical therapy] - Prof. Giuseppe Viale, IT
Methodology in Bio-Markers Research and Validation - Prof. Dr. Nadia Harbeck, DE
- The challenge of statistical validation of biomarkers - Prof. Marc Buyse, BE
Opening Keynote Lecture: Interrogating the architecture of cancer genome - Dr. Martine Piccart, BE
- Interrogating the architecture of cancer genomes [5. Molecular biology (pre-clinical)] - Dr. Peter Campbell, UK
- Translational implications [7. Miscellaneous] - Dr. Judy Garber, US
DNA Repair as a Treatment Target - Professor Michael Gnant, AT
- Early phase proof of concept studies and rationale for patient selection - Dr. Andrew Tutt, UK
- Early data and future plans for combinations of PARP inhibitros and chemotherapy [6. New drug development] - Dr. Judith Balmaña, ES
Best Abstracts - Clifford Hudis, US, Prof. Angelo Di Leo, IT, Dr. Fabrice André, FR, Prof. John Bartlett, UK
- Gene Expression Profiling of RNA from Formalin-Fixed, Paraffin-Embedded (FFPE) and Fresh Frozen (FF) Breast Cancer Tissues using the DASL gene expression assay [1. Detection and diagnosis] - Lorenza Mittempergher, NL
- Robustness of breast cancer molecular subtypes identification [5. Molecular biology (pre-clinical)] - Dr. Benjamin Haibe-Kains, BE
- Tracing tumour lineage and progression through genomic copy number profiling at the single cell level [5. Molecular biology (pre-clinical)] - Prof. James Hicks, US
- Discussant, Abstracts 96O, 97O and 98O - Dr. Fabrice André, FR
- Discussant, Abstracts 25O and 26O - Prof. John Bartlett, UK
Keynote Lecture: A decade of translational research in breast cancer - Prof. Giuseppe Viale, IT, Dr. William Fraser Symmans, US
- A decade of translational research in breast cancer: conquests and questions for the future - Prof. Larry Norton, US
The next wave of molecular therapies - Prof.Dr. Jean-Charles Soria, FR, Professor Stephen Johnston, UK, Neil Rosen, US
- Functional imaging: protein and protein interactions as a potential companion of diagnostic tools [4. Imaging] - Prof. Dr. med Tony Ng, UK
Innovative Trials Design - Dr. Richard Gelber, US
- The neo-adjuvant model to accelerate drug development and bio-markers discovery [7. Miscellaneous] - Dr. Christos Sotiriou, BE
- Will neo-adjuvant trial results impact on future treatment practice? [3. Adjuvant medical therapy] - Dr. Eric Winer, US
Practice-Changing Discoveries in Translational Research - Prof. Aron Goldhirsch, IT
- Cytotoxics as targeted agents. Dreams or the future? [3. Adjuvant medical therapy] - Prof. John Bartlett, UK
Special Educational Session: Tailoring of Endocrine Therapy - Dr. Kent Osborne, US, Dr. Eric Winer, US, Dr. Martine Piccart, BE
Keynote Lecture: Cancer metabolism as a potential treatment target - Prof. Dr. Med Heikki Joensuu, FI
- Cancer metabolism as a potential treatment target [5. Molecular biology (pre-clinical)] - Prof. David Hardie, UK
Breast Cancer Initiation and Metastatic Progression - Neil Rosen, US, Dr. Pamela Goodwin, CA
- Breast Cancer Metastases and Clinical Progression Clinical Perspectives [1. Detection and diagnosis] - Dr. Daniel F. Hayes, US
Is Anti-angiogenic Therapy Dead in Breast Cancer? - Jonas Bergh, SE
- A clinician's point of view - Dr. David Miles, UK